Coronation Fund Managers Ltd. purchased a new position in shares of Humana Inc (NYSE:HUM) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 65,690 shares of the insurance provider’s stock, valued at approximately $17,428,000. Humana accounts for approximately 0.6% of Coronation Fund Managers Ltd.’s investment portfolio, making the stock its 28th largest holding.
Other institutional investors and hedge funds have also made changes to their positions in the company. Whittier Trust Co. bought a new position in shares of Humana in the second quarter valued at approximately $27,000. Destination Wealth Management raised its stake in shares of Humana by 130.0% in the first quarter. Destination Wealth Management now owns 115 shares of the insurance provider’s stock valued at $31,000 after acquiring an additional 65 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. bought a new position in shares of Humana in the second quarter valued at approximately $36,000. Evolution Wealth Advisors LLC bought a new position in shares of Humana in the second quarter valued at approximately $46,000. Finally, Zions Bancorporation N.A. bought a new position in shares of Humana in the first quarter valued at approximately $51,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.
HUM traded down $3.51 during trading on Monday, reaching $290.42. 1,622 shares of the company’s stock were exchanged, compared to its average volume of 1,143,401. The firm has a fifty day moving average of $272.19. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.75 and a quick ratio of 1.65. Humana Inc has a fifty-two week low of $225.65 and a fifty-two week high of $355.88. The firm has a market cap of $39.19 billion, a price-to-earnings ratio of 19.85, a PEG ratio of 1.27 and a beta of 0.85.
HUM has been the subject of a number of research analyst reports. Barclays cut their target price on shares of Humana from $351.00 to $327.00 and set an “overweight” rating for the company in a research note on Wednesday, April 17th. Morgan Stanley lowered their price target on shares of Humana from $331.00 to $315.00 and set an “overweight” rating for the company in a report on Friday, July 12th. JPMorgan Chase & Co. raised their price target on shares of Humana from $288.00 to $322.00 and gave the company an “overweight” rating in a report on Thursday. Piper Jaffray Companies raised their price target on shares of Humana from $315.00 to $341.00 and gave the company an “overweight” rating in a report on Thursday. Finally, Zacks Investment Research lowered shares of Humana from a “hold” rating to a “sell” rating in a report on Thursday, April 11th. One analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $341.21.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.